Overview

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

Status:
Not yet recruiting

Trial end date:
2025-10-31

Target enrollment:

Participant gender:

Summary

This study is designed to identify the best tolerated doses of Lutathera® and Azedra® when co-administered to treat midgut neuroendocrine tumors. These drugs are radioactive drugs, known as radionuclide therapy, and are both approved in the treatment of midgut neuroendocrine tumor as single agents (not together). Currently, the safest and best tolerated doses of these drugs (when combined) is unknown. That is the purpose of this clinical trial.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

David Bushnell

Collaborators:

National Cancer Institute (NCI)
National Institutes of Health (NIH)
Progenics Pharmaceuticals, Inc.

Treatments:

3-Iodobenzylguanidine
Lutetium Lu 177 dotatate